Advertisement
Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

[Comment] PARP inhibitors: pitfalls and promises

20:41 EDT 27 Jun 2013 | The Lancet

Enthusiasm swelled for inhibition of poly(ADP-ribose) polymerase (PARP) as a treatment strategy in oncology when the oral inhibitor of PARP-1 and PARP-2 olaparib produced durable responses in patients with ovarian and breast cancer and BRCA mutations...

Original Article: [Comment] PARP inhibitors: pitfalls and promises

NEXT ARTICLE

More From BioPortfolio on "[Comment] PARP inhibitors: pitfalls and promises"

Search BioPortfolio:
Advertisement
Advertisement

Searches Linking to this Story